Immunological Markers of Optimal Response to Natalizumab in Multiple Sclerosis

Archives of Neurology

Volumn 69, Issue 2, 2012, Pages 191-197

  Villar, Luisa M ^a,b   García Sánchez, María I ^a,e   Costa Frossard, Lucienne ^a,b,c   Espiño, Mercedes ^a,b   Roldán, Ernesto ^a,b   Páramo, Dolores ^a,e   Lucas, Miguel ^a,e   Izquierdo, Guillermo ^a,e   Álvarez Cermeño, José C ^a,b,c,d  

^a Hospital Universitario Quironsalud Madrid Red Española de Esclerosis Múltiple REEM   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Department of Neurology ^*  (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NATALIZUMAB;

ADULT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MIGRATION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; NATIONAL HEALTH SERVICE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SPAIN; TERTIARY HEALTH CARE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD5; B-LYMPHOCYTES; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEUKOCYTE COUNT; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84856870952     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.971     Document Type: Article

References (27)

1. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2007;61(4):300-306. (Pubitemid 46676729)
2. Polman CH, O'Connor PW, Havrdova E, et al AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
3. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260.
4. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology. 2010;74(suppl 3):S3-S7.
5. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5):743-747. (Pubitemid 43673151)
6. Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72(5):396-401.
7. Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler. 2010;16(2):208-217.
8. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006;59(5):748-754. (Pubitemid 43673152)
9. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-231. (Pubitemid 13158528)
11. Villar LM, Sádaba MC, Roldán E, et al. Intrathecal synthesis of oligoclonal IgMagainst myelin lipids predicts an aggressive disease course in MS. J Clin Invest. 2005;115(1):187-194. (Pubitemid 40385520)
12. Sádaba MC, González Porqué P, Masjuan J, Alvarez-Cermeño JC, Bootello A, Villar LM. An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Methods. 2004;284(1-2):141- 145. (Pubitemid 38084921)
13. Villar LM, González-Porqué P, Masjuán J, Alvarez-Cermeño JC, Bootello A, Keir G. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J Immunol Methods. 2001;258(1-2):151-155. (Pubitemid 33016535)
14. Lefvert AK, Link H. IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol. 1985;17(1):13-20. (Pubitemid 15156045)
15. Forsberg P, Henriksson A, Link H, Öhman S. Reference values for CSF-IgM, CSF-IgM/S-IgM ratio and IgM index, and its application to patients with multiple sclerosis and aseptic meningoencephalitis. Scand J Clin Lab Invest. 1984;44(1):7-12. (Pubitemid 14171497)
16. Gunnarsson M, Malmeström C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011;69(1):83-89.
17. Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002;59(4):555-559. (Pubitemid 34919989)
18. Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol. 2003;53(2):222-226. (Pubitemid 36164004)
19. Perini P, Ranzato F, Calabrese M, Battistin L, Gallo P. Intrathecal IgM production at clinical onset correlates with amore severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(8):953-955. (Pubitemid 44174082)
20. Jongen PJ, Lycklama a Nijeholt G, Lamers KJ, et al. Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. Eur Neurol. 2007;58(2):90-95.
21. Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A multifactorial prognostic index in multiple sclerosis: cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol. 2008;255(7):1023-1031.
22. Saiz A, Carreras E, Berenguer J, et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology. 2001;56(8):1084-1089. (Pubitemid 32336318)
23. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180(1-2):63-70. (Pubitemid 44767709)
24. Confavreux C, Chapuis-Cellier C, Arnaud P, Robert O, Aimard G, Devic M. Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. J Neurol Neurosurg Psychiatry. 1986;49(11):1308-1312. (Pubitemid 17174036)
25. Postigo AA, Pulido R, Campanero MR, et al. Differential expression of VLA-4 integrin by resident and peripheral blood B lymphocytes: acquisition of functionally active alpha 4 beta 1-fibronectin receptors upon B cell activation. Eur J Immunol. 1991;21(10):2437-2445.
26. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005;128(Pt 7):1667-1676. (Pubitemid 41373685)
27. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol. 2002;169(8):4213-4221. (Pubitemid 35178192)